SecBot SecBot
8-K ·Filed Feb 27, 2026

LRMR

Larimar Therapeutics, Inc.
NEUTRAL
Impact 5/10
Horizonimmediate Processed8mo ago SEC0001193125-26-077646
8-K Item 1.01 + 5.02 (likely routine officer/director compensation agreement)
Actionable Insight • Neutral

Monitor the offering close on February 27, 2026, and watch for any subsequent announcements regarding the specific allocation of the $107.6 million in net proceeds, particularly how much will be directed toward advancing Larimar's clinical programs versus general corporate expenses.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$5.31
T+0 close · Feb 27, 2026 · via day close
Latest settled
−34.65%
T+60 · $3.47
Vs SPY
−44.04%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Feb 27 $5.31entry
  2. T+1 · 9mo ago −1.51%α −1.56% · $5.23
  3. T+5 · 9mo ago −1.69%α +0.29% · $5.22
  4. T+20 · 8mo ago −12.99%α −5.44% · $4.62
  5. T+60 · 6mo ago −34.65%α −44.04% · $3.47
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Larimar Therapeutics is conducting a follow-on public offering of 20 million shares at $5.00 per share, with underwriters exercising their full option to purchase an additional 3 million shares, resulting in expected net proceeds of approximately $107.6 million. The company plans to use the proceeds for general corporate purposes, including advancing its clinical programs and expanding operations.

Key Financial Metrics

Deal Value
$115.0M

Key Facts

  • Larimar Therapeutics is offering 20 million shares of common stock at $5.00 per share
  • Underwriters exercised their full option to purchase an additional 3 million shares
  • Expected net proceeds after underwriting discounts and commissions are approximately $107.6 million
  • J.P. Morgan Securities LLC and Guggenheim Securities, LLC are acting as joint bookrunning managers
  • The offering is expected to close on February 27, 2026, subject to customary closing conditions

Financial Impact

Approximately $107.6 million in net proceeds after underwriting discounts and commissions from the sale of 23 million shares at $5.00 per share

cashdilutionmarket_cap

Risk Factors

  • Dilution to existing shareholders from the issuance of 23 million new shares
  • Potential downward pressure on stock price due to increased share supply
  • Uncertainty around how effectively the company will deploy the raised capital

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-077646
Document: d120172d8k.htm0001193125-26-077646
Document: d120172dex51.htm0001193125-26-077646
Document: 0001193125-26-077646-index-headers.html0001193125-26-077646
Document: 0001193125-26-077646-index.html0001193125-26-077646
Document: 0001193125-26-077646.txt0001193125-26-077646

US Market Status

Market Closed · Opens in 6h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Feb 27, 2026